Regorafenib approved by NICE for advancedGIST

Regorafenib approved by NICE for advancedGIST PharmacoEconomics & Outcomes News 792, p36 - 2 Dec 2017 Regorafenib approved by NICE for advanced GIST The UK National Institute for Health and Care Excellence (NICE) has recommended regorafenib (Stivarga) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST), reported Selina McKee in Pharma Times. Regorafenib will be available for routine funding within the NHS at the discount agreed with Bayer in a confidential patient access scheme, for adults with GIST with disease progression on, or who were intolerant to, previous imatinib and sunitinib therapy, and have an Eastern Cooperative Oncology Group performance status of 0 to 1. According to NICE, regorafenib meets the criteria for a life-extending end-of-life treatment, and has an estimated cost-effectiveness ratio of £44 000 per QALY gained compared with best supportive care. * National Health Service McKee S. Bayer’s Stivarga wins NICE approval for GIST Pharma Times : 20 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ bayers_stivarga_wins_nice_approval_for_gist_1211984 803284556 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Regorafenib approved by NICE for advancedGIST

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/regorafenib-approved-by-nice-for-advancedgist-Xtid0CvaeO
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4559-6
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p36 - 2 Dec 2017 Regorafenib approved by NICE for advanced GIST The UK National Institute for Health and Care Excellence (NICE) has recommended regorafenib (Stivarga) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST), reported Selina McKee in Pharma Times. Regorafenib will be available for routine funding within the NHS at the discount agreed with Bayer in a confidential patient access scheme, for adults with GIST with disease progression on, or who were intolerant to, previous imatinib and sunitinib therapy, and have an Eastern Cooperative Oncology Group performance status of 0 to 1. According to NICE, regorafenib meets the criteria for a life-extending end-of-life treatment, and has an estimated cost-effectiveness ratio of £44 000 per QALY gained compared with best supportive care. * National Health Service McKee S. Bayer’s Stivarga wins NICE approval for GIST Pharma Times : 20 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ bayers_stivarga_wins_nice_approval_for_gist_1211984 803284556 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off